4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-24-045196
Chief Executive Officer sold 19,582 shares at an average $59.91 ($1,173,232)
- Chief Executive Officer acquired 19,582 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2024-04-15 | Option exercise 10b5-1 | +19,582 | $19.12 | $374,408 | 227,704 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-04-15 | Sale 10b5-1 | −18,378 | $59.88 | $1,100,510 | 209,326 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-04-15 | Sale 10b5-1 | −1,204 | $60.40 | $72,722 | 208,122 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2024-04-15 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,582 | 0 | D | ||
| Open-market sales · 19,582 sh · avg $59.91 · $1,173,232 | |||||||
Loading xslF345X05/ownership.xml…